

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 May 2023 (04.05.2023)



(10) International Publication Number
WO 2023/076523 A1

(51) International Patent Classification:

C12N 15/62 (2006.01) C07K 14/705 (2006.01)
A61K 35/17 (2015.01) C12N 5/10 (2006.01)

(21) International Application Number:

PCT/US2022/048097

(22) International Filing Date:

27 October 2022 (27.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/272,613 27 October 2021 (27.10.2021) US

(71) Applicant: **ADICET THERAPEUTICS, INC.** [US/US];
1000 Bridge Pkwy, Redwood City, CA 94065 (US).

(72) Inventors: **AFTAB, Blake, T.**; c/o Adicet Bio, Inc., 1000
Bridge Pkwy, Redwood City, CA 94065 (US). **HER-**
RMAN, Marissa; c/o Adicet Bio, Inc., 1000 Bridge Pkwy,
Redwood City, CA 94065 (US). **ROMERO, Jason**; c/o
Adicet Bio, Inc., 1000 Bridge Pkwy, Redwood City, CA
94065 (US). **SATPAYEV, Daulet**; c/o Adicet Bio, Inc.,
1000 Bridge Pkwy, Redwood City, CA 94065 (US). **AB-**
BOT, Stewart; c/o Adicet Bio, Inc., 1000 Bridge Pkwy,
Redwood City, CA 94065 (US). **BHAT, Arun**; c/o Adicet

Bio, Inc., 1000 Bridge Pkwy, Redwood City, CA 94065
(US). **WONG, Jonathan**; c/o Adicet Bio, Inc., 1000 Bridge
Pkwy, Redwood City, CA 94065 (US).


(74) Agent: **LORENZ, Todd** et al.; Squire Patton Boggs, 475
Sansome Street, 16th Floor, San Francisco, CA 94111 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: CHIMERIC ADAPTOR POLYPEPTIDES

FIG. 1D



(57) Abstract: Aspects of the disclosure include compositions and methods for treatment of a wide variety of diseases/conditions with engineered host cells. In some embodiments, the engineered host cells comprise a chimeric adaptor (CAD) polypeptide comprising DAP 10. The CAD polypeptide comprises substitution mutations and/or additional protein domains that function in conjunction with associated receptors to enhance cell survival and proliferation of the host cells, and to enhance cell killing activities of non-host cells.

[Continued on next page]

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*